|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: POLI |
Gene summary for POLI |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | POLI | Gene ID | 11201 |
| Gene name | DNA polymerase iota | |
| Gene Alias | RAD30B | |
| Cytomap | 18q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000731 | UniProtAcc | Q9UNA4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11201 | POLI | Dong_P3 | Human | Prostate | Tumor | 4.04e-02 | 8.41e-02 | 0.0278 |
| 11201 | POLI | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 3.52e-03 | 3.76e-01 | 0.1633 |
| 11201 | POLI | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.47e-05 | 4.13e-01 | 0.1608 |
| 11201 | POLI | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 2.42e-07 | 5.33e-01 | 0.1604 |
| 11201 | POLI | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 1.66e-03 | 5.70e-01 | 0.1622 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007189714 | Prostate | Tumor | DNA biosynthetic process | 51/3246 | 180/18723 | 1.63e-04 | 1.46e-03 | 51 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| POLI | SNV | Missense_Mutation | c.2140T>G | p.Tyr714Asp | p.Y714D | Q9UNA4 | protein_coding | deleterious(0.04) | possibly_damaging(0.768) | TCGA-A2-A0D3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| POLI | SNV | Missense_Mutation | c.2189G>C | p.Arg730Thr | p.R730T | Q9UNA4 | protein_coding | tolerated_low_confidence(0.1) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| POLI | insertion | In_Frame_Ins | novel | c.2204_2205insCTTGCAGAGTGAGCAACTTTTCTCCAGAAA | p.Phe735_His736insLeuGlnSerGluGlnLeuPheSerArgAsn | p.F735_H736insLQSEQLFSRN | Q9UNA4 | protein_coding | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| POLI | insertion | In_Frame_Ins | novel | c.878_879insATCTTATTA | p.Ile293_Leu294insSerTyrTyr | p.I293_L294insSYY | Q9UNA4 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| POLI | SNV | Missense_Mutation | novel | c.1363N>T | p.Pro455Ser | p.P455S | Q9UNA4 | protein_coding | tolerated(0.17) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| POLI | SNV | Missense_Mutation | c.2165A>G | p.Lys722Arg | p.K722R | Q9UNA4 | protein_coding | tolerated(0.12) | benign(0.011) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| POLI | SNV | Missense_Mutation | rs759154060 | c.625N>T | p.Arg209Trp | p.R209W | Q9UNA4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| POLI | SNV | Missense_Mutation | c.1453N>C | p.Asn485His | p.N485H | Q9UNA4 | protein_coding | deleterious(0) | possibly_damaging(0.635) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| POLI | SNV | Missense_Mutation | c.1720A>G | p.Lys574Glu | p.K574E | Q9UNA4 | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| POLI | SNV | Missense_Mutation | c.1505N>T | p.Ser502Phe | p.S502F | Q9UNA4 | protein_coding | tolerated(0.21) | benign(0.165) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 11201 | POLI | DNA REPAIR | RHEIN | RHEIN | ||
| 11201 | POLI | DNA REPAIR | TETRAIDOFLUORESCEIN | TETRAIDOFLUORESCEIN | ||
| 11201 | POLI | DNA REPAIR | (-)-DICENTRINE | CHEMBL478754 | ||
| 11201 | POLI | DNA REPAIR | SCLEROTIORIN | SCLEROTIORIN | ||
| 11201 | POLI | DNA REPAIR | 9,10-PHENANTHRENEQUINONE | 9,10-PHENANTHRENEQUINONE | ||
| 11201 | POLI | DNA REPAIR | FURAMIDINE | FURAMIDINE | ||
| 11201 | POLI | DNA REPAIR | 5,6,7,8,4'-PENTAHYDROXYFLAVONE | CHEMBL234338 | ||
| 11201 | POLI | DNA REPAIR | CEPHALOCHROMIN | CEPHALOCHROMIN | ||
| 11201 | POLI | DNA REPAIR | HOMIDIUM BROMIDE | HOMIDIUM BROMIDE | ||
| 11201 | POLI | DNA REPAIR | LAVENDUSTIN B | LAVENDUSTIN B |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |